{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:42Z","timestamp":1789981302812,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05593-2","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:15:39Z","timestamp":1781756139000},"page":"20085-20089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric hepatic laboratory reporting with CFTR modulators: a FAERS pharmacovigilance study"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7308-2069","authenticated-orcid":false,"given":"Xiaogao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"5593_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","volume":"78","author":"FAJA Bodewes","year":"2024","unstructured":"Bodewes FAJA, Freeman AJ, Weymann A et al (2024) Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN position paper. J Pediatr Gastroenterol Nutr 78(1):153\u2013165. https:\/\/doi.org\/10.1097\/MPG.0000000000003944","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5593_CR2","volume-title":"Practical aspects of signal detection in pharmacovigilance","author":"Council for International Organizations of Medical Sciences Working Group VIII","year":"2010","unstructured":"Council for International Organizations of Medical Sciences Working Group VIII (2010) Practical aspects of signal detection in pharmacovigilance. CIOMS, Geneva"},{"key":"5593_CR3","unstructured":"European Medicines Agency (2026) European database of suspected adverse drug reaction reports. https:\/\/www.adrreports.eu\/en\/index.html. Accessed 30 Apr 2026"},{"issue":"6","key":"5593_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"issue":"1","key":"5593_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski JL, Hoppe JE, Mall MA et al (2023) Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med 208(1):59\u201367. https:\/\/doi.org\/10.1164\/rccm.202301-0084OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5593_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jcf.2025.08.008","volume":"24","author":"C H\u00f8jte","year":"2025","unstructured":"H\u00f8jte C, Olsen MF, Faurholt-Jepsen D et al (2025) Severe hepatotoxicity is uncommon following the introduction of elexacaftor\/tezacaftor\/ivacaftor: a real-world two-years follow-up study of the Danish cystic fibrosis cohort. J Cyst Fibros 24(5):998\u20131005. https:\/\/doi.org\/10.1016\/j.jcf.2025.08.008","journal-title":"J Cyst Fibros"},{"key":"5593_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall MA, Brugha R, Gartner S et al (2022) Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study. Am J Respir Crit Care Med 206:1361\u20131369. https:\/\/doi.org\/10.1164\/rccm.202202-0392OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5593_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Information on the dataset download page for suspected adverse reaction reports. https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0004.html. Accessed 30 Apr 2026"},{"issue":"5","key":"5593_CR9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","volume":"79","author":"ZM Sellers","year":"2024","unstructured":"Sellers ZM, Assis DN, Paranjape SM et al (2024) Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 79(5):1220\u20131238. https:\/\/doi.org\/10.1097\/HEP.0000000000000646","journal-title":"Hepatology"},{"issue":"3","key":"5593_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","volume":"23","author":"A Shi","year":"2024","unstructured":"Shi A, Nguyen H, Kuo CB, Beringer PM (2024) Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS). J Cyst Fibros 23(3):566\u2013572. https:\/\/doi.org\/10.1016\/j.jcf.2024.01.001","journal-title":"J Cyst Fibros"},{"key":"5593_CR11","unstructured":"US Food and Drug Administration (2026a) ALYFTREK prescribing information. Revised March 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/218730s003lbl.pdf. Accessed 30 Apr 2026"},{"key":"5593_CR12","unstructured":"US Food and Drug Administration (2026b) E2D(R1) Post-approval safety data: definitions and standards for management and reporting of individual case safety reports. March 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case. Accessed 5 May 2026"},{"key":"5593_CR13","unstructured":"US Food and Drug Administration (2026c) openFDA drug adverse event API. https:\/\/open.fda.gov\/apis\/drug\/event\/. Accessed 30 Apr 2026"},{"key":"5593_CR14","unstructured":"US Food and Drug Administration (2026d) openFDA FAERS data. https:\/\/open.fda.gov\/data\/faers\/. Accessed 30 Apr 2026"},{"key":"5593_CR15","unstructured":"US Food and Drug Administration (2026e) TRIKAFTA prescribing information. Revised March 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/217660s010lbl.pdf. Accessed 30 Apr 2026"},{"key":"5593_CR16","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/sim.1157","volume":"21","author":"PGM van der Heijden","year":"2002","unstructured":"van der Heijden PGM, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027\u20132044. https:\/\/doi.org\/10.1002\/sim.1157","journal-title":"Stat Med"},{"issue":"1","key":"5593_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","volume":"208","author":"CE Wainwright","year":"2023","unstructured":"Wainwright CE, McColley SA, McNally P et al (2023) Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial. Am J Respir Crit Care Med 208(1):68\u201378. https:\/\/doi.org\/10.1164\/rccm.202301-0021OC","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05593-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:14:10Z","timestamp":1789978450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5593"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05593-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study used public regulatory adverse-event data without direct identifiers and did not require institutional ethics approval.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data and analysis tables were generated in-house from public source data. No paper mill, external service laboratory, or commercial manuscript service was used. No AI tool was used for the generation of text or figures.","order":6,"name":"Ethics","label":"Integrity statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}